The Post-Traumatic Stress Disorder Therapeutics Market size is estimated to reach $17.3 billion by 2028, growing at a CAGR of 4.5% during the forecast period 2023-2028. The growth of the post-traumatic stress disorder therapeutics market is greatly fueled by the rising prevalence of post-traumatic stress disorder among women and a boost in the count of clinical trials regarding post-traumatic stress disorder treatment. As per research, women are twice as probable to cultivate PTSD, endure a lengthier duration of post-traumatic symptoms and demonstrate greater sensitivity to stimuli that recall the trauma. Clinical trials are frequently organized by hospitals, universities or contract research organizations employed by pharmaceutical firms. Physicians and mental health professionals may be contacted to receive information regarding the enrolment for a PTSD clinical trial in a specified area. This is further fueling the growth of the Post-traumatic Stress Disorder Therapeutics Industry, thereby contributing to the Post-traumatic Stress Disorder Therapeutics Industry Outlook. Antidepressants are typically recommended for posttraumatic stress disorder (PTSD). An analysis of the accessible literature backs the efficiency of monoamine oxidase inhibitors (MAOIs) in treating post-traumatic stress disorder (PTSD). As per outcomes of a current investigation, beta-blockers propranolol may be a new and efficient treatment for Post-traumatic Stress Disorder (PTSD).

Post-Traumatic Stress Disorder Therapeutics Market Growth Drivers:

Surging Applications of Antidepressants and Beta-blockers:

Usually, Selective Serotonin Reuptake Inhibitors (SSRIs) are recommended for Post-traumatic Stress Disorder (PTSD). They are by far the most typically recommended form of antidepressants owing to their lesser side effects. SSRIs perform by obstructing the reuptake of serotonin into the nerve cell that discharged it. Nearly all people with acute PTSD would consume medicines for 6-12 months. Beta-blockers like Propranolol have long been utilized "off-label" to treat anxiety patients due to their capability to obstruct or reduce "peripheral autonomic activation." The surging applications of antidepressants and beta-blockers are therefore driving the growth of the Post-traumatic Stress Disorder Therapeutics Market.

For More Queries About "Post-Traumatic Stress Disorder Therapeutics Market" @

Soaring Number of Therapies and Activities to Alleviate PTSD Symptoms:

As per the website:, 67% of people exposed to mass violence have been demonstrated to develop PTSD. In the UK, there are 2 principal psychological treatments suggested for treating PTSD & C-PTSD (Complex Post-traumatic Stress Disorder): Eye Movement Desensitisation Reprocessing (EMDR) and trauma-focused cognitive behavioral therapy (CBT). Certain techniques utilized in the treatment of PTSD include yoga, meditation and havening technique. Monoamine oxidase A is one of the key enzymes mediating the turnover of noradrenaline. The current findings recommend monoamine oxidase A gene hypermethylation. The soaring number of therapies and activities to alleviate PTSD symptoms are therefore propelling the growth of the Post-traumatic Stress Disorder Therapeutics Industry, thereby contributing to the Post-traumatic Stress Disorder Therapeutics Industry Outlook.


In May 2022, Eli Lilly and Co. pronounced that it would construct two manufacturing facilities in Boone County, investing greater than $2.1 billion. The Lilly project proposes to develop 500 jobs.

Post-Traumatic Stress Disorder Therapeutics Market: Competitive Landscape

Key companies holding major shares in the Post-traumatic Stress Disorder Therapeutics Market are AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd, Eli Lilly and Company, GlaxoSmithKline Plc, H. Lund beck AS, Pfizer Inc., Lupin Limited, Aurobindo Pharma Limited and Otsuka Pharmaceutical Co. Ltd.

To request for a quote, provide your details in the below link:

Media Contact:

Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.